Modified aav vectors that dampen the humoral immune response
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsArun Srivastava, Keyun Qing
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsArun Srivastava, Keyun Qing
Estimating the term…
Provided herein are compositions of recombinant adeno-associated virus (rAAV) particles capable of dampening the humoral immune response against rAAV in the host into which the rAAV particles are introduced. The modified genomes of these rAAV particles comprise heterologous insert nucleic acid and/or inverted terminal repeat (ITR) sequences containing one or more sequences associated with the human leukocyte antigen gene complex DR (HLA-DR) promoter. Also provided herein are methods for transducing host cells with modified rAAV particles to induce a dampened humoral immune responses in order to improve transduction efficiencies. Also provided herein are complexes comprising a modified rAAV particle and a Regulatory Factor X (RFX) transcription factor.
A recombinant adeno-associated virus (rAAV) particle, comprising:
A recombinant adeno-associated virus (rAAV) particle, comprising:
A recombinant adeno-associated virus (rAAV) particle, comprising:
Dependencies are inferred from the claim text.